- Home
- CHY vs PHAT Comparison
CHY vs PHAT Comparison
Compare CHY & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | PHAT |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.9M | 1.0B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CHY | PHAT |
|---|---|---|
| Price | $11.98 | $11.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 192.5K | ★ 898.5K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $83.18 |
| Revenue Next Year | N/A | $61.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $9.00 | $2.21 |
| 52 Week High | $12.12 | $18.31 |
Technical Indicators
Market Signals| Indicator | CHY | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 39.53 |
| Support Level | $10.72 | $10.65 |
| Resistance Level | N/A | $12.77 |
| Average True Range (ATR) | 0.13 | 0.87 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 59.32 | 14.01 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.